Prevention of Post-spinal Anesthesia Hypotension in Caesarean Delivery Using Delayed Supine Positioning

Hypotension Clinical Trial

Official title:

Prevention of Post-spinal Anesthesia Hypotension in Caesarean Delivery Using Delayed Supine Positioning: a Randomized Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04777123
• Other study ID #: MD-85-2019
• Status: Not yet recruiting
• Phase: N/A
• Start date: March 2021
• Est. completion date: June 2021

Study information

• Verified date: February 2021
• Source: Cairo University
• Contact: Maha Mostafa, M.D
• Phone: 01000365115
• Email: maha.mostafa[@]cu.edu.eg
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Maternal hypotension is a common complication after spinal anaesthesia for caesarean delivery. Prophylaxis against post-spinal hypotension (PSH) during caesarean delivery would prevent serious maternal and fetal complications. Various methods had been investigated for prophylaxis against maternal hypotension. The basic components of management of PSH are: 1. Fluid loading. 2. Pharmacological agents. 3. Positioning protocols. Although Fluid loading is superior to non-loading protocols during caesarean delivery, the incidence of Post-spinal hypotension is high with all fluid loading protocols. Thus; the value of fluid loading in caesarean delivery could not be used solely for prevention of PSH. Using vasopressors for prophylaxis against PSH is nearly fundamental during caesarean delivery. However, vasopressors are not devoid of side effects such as reflex bradycardia after phenylephrine and fetal acidosis after ephedrine. Thus, combining vasopressor prophylaxis and non-pharmacological protocols would help to decrease the dose of vasopressors, and consequently decreasing their side effects. Ondansetron had been also reported as a useful prophylactic drug from PSH with minimal side effects. Positioning protocols, such as operating table tilting or flexing, the use of wedges or mechanical displacers, leg wrapping or sequential compression devices, head down and head up positioning aim to reversing aortocaval compression and/or increasing venous return. The sitting position for a short period after spinal block in order to slow the onset of the spinal block. Keeping the patient in the sitting position after spinal block would also prevent extension of local anaesthetic solution to upper thoracic dermatomes which is an important factor in preventing maternal hypotension. no previous reports had evaluated the impact of sitting position within the context of a multimodal protocol for prophylaxis against maternal hypotension. In this study, we aim to evaluate the impact of 2-minute sitting position after spinal anesthesia on maternal hemodynamics when combined with prophylactic norepinephrine infusion plus preoperative bolus of ondansetron. We aim to reach the best possible maternal hemodynamic profile in addition to maintenance of adequate block level.

Description:

Upon arrival to operating room, Monitors will be applied (electrocardiography - pulse oximetry - non-invasive blood pressure monitor). All measurements will be taken before IV line insertion and premedications. Baseline systolic blood pressure will be obtained in the supine position as the mean of three consecutive readings at 2-minute intervals with a difference of less than 10%. After insertion of a peripheral 18-gauge line with a three way valve for fluids and vasopressor infusion; Premedication's with ranitidine (50mg) and ondansetron (4 mg) will be administered. Subarachnoid block (SAB) will be done in sitting position under complete asepsis in L3-L4 or L4-L5 interspace using 25 g spinal needle. 11 mg of 0.5% intrathecal hyperbaric Bupivacaine and 25um fentanyl will be administered. Block success will be assessed using pinprick or sensation to cold besides adequate motor block. Patients with failed SAB (Defined as sensory level below T4) will be excluded as well as patients with high spinal block (defined as spinal anaesthesia in which spinal denervation extends to second or third thoracic dermatome or sometimes up to cervical dermatomes). Co-hydration will be continued up to a maximum of 1.5 litres (patients with intraoperative blood loss over 1000 ml will be excluded from the study). After delivery of the foetus, oxytocin will be given as an initial bolus of 0.5 IU over five seconds followed by 40 mIU/minute infusion. Inspired air will be supplemented with oxygen 3 l/min via a nasal catheter until delivery. Continuous norepinephrine fixed rate infusion will be given to both groups as 5 mcg norepinephrine bolus at the same time cerebrospinal fluid obtained followed by norepinephrine infusion in a starting dose of 0.05 mcg/Kg/min. Norepinephrine will be prepared as 8 mcg/mL and will be delivered using a syringe pump. Post-spinal hypotension (defined as decreased SBP less than 80% of the baseline reading during the period from intrathecal injection to delivery of the foetus) will be managed by IV ephedrine 9 mg. Severe post-spinal hypotension (defined as decreased SBP less than 60% of the baseline reading) will be managed by IV ephedrine 15 mg. Additional vasopressor bolus was given if SBP did not respond to the first dose within 2 minutes. Intraoperative hypertension (defined as SBP >120% of the baseline reading) will be managed by stopping norepinephrine infusion. The infusion will be resumed when blood pressure returned to its normal value. Intraoperative bradycardia (defined as heart rate less than 55 bpm without hypotension during the period from intrathecal injection to delivery of the fetus) will be managed by stopping the vasopressor infusion. If bradycardia was associated with hypotension, the patient was managed by IV ephedrine 9 mg. If bradycardia persisted after the previous measures, an IV atropine bolus (0.5 mg) will be given. Norepinephrine total dose will be calculated in both groups for comparison purposes. Measurements will be taken every 2 minutes.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 84
• Est. completion date: June 2021
• Est. primary completion date: June 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Full term (above 37 weeks gestation).
• Singleton.
• Pregnant woman ASA II scheduled for elective caesarean section aged between 18 and 35 years.

Exclusion Criteria:

• Contraindications to spinal anaesthesia.
• Obese patients (body mass index >35).
• Peripartum bleeding.
• Impaired cardiac contractility (Ejection fraction<45%).
• Cardiac arrhythmias (I.e. any rhythm other than normal sinus rhythm and sinus tachycardia).
• Valvular heart lesions (I.e. moderate to severe valve lesions).
• Pre-existing hypertension, pregnancy induced hypertensive disorders.
• Fetal abnormalities.
• Intraoperative blood loss over 1000 ml and failed/ high subarachnoid block.

Related Conditions & MeSH terms

• Cesarean Section
• Hypotension
• Spinal Anaesthesia

Intervention

Other:
• sitting position
patients will be left seated for 2 minutes after subarachnoid injection

Locations

Country	Name	City	State
Egypt	Cairo University	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	average systolic blood pressure	mmHg	immediately after SAB till delivery of fetus
Secondary	post-spinal anaesthesia hypotension	frequency of patients with decreased systolic blood pressure less than 80% of the baseline reading	immediately after SAB till delivery of fetus
Secondary	severe post-spinal anaesthesia hypotension	frequency of patients with decreased systolic blood pressure less than 60% of the baseline reading	immediately after SAB till delivery of fetus
Secondary	reactive hypertension	percentage of patients with increased systolic blood pressure more than 120% of the baseline reading	immediately after SAB till delivery of fetus
Secondary	nausea and vomiting	frequency	immediately after SAB till delivery of fetus
Secondary	norepinephrine requirement	mcg	immediately after SAB till delivery of fetus
Secondary	ephedrine requirement	mg	immediately after SAB till delivery of fetus
Secondary	atropine requirement	mg	immediately after SAB till delivery of fetus
Secondary	umbilical cord blood gases	pH	1 minutes after delivery
Secondary	Apgar score	assessing the appearance, pulse, grimace, activity, respiration on a scale from zero to two, then summing up the five values thus obtained. The resulting score ranges from zero to 10.	at 1 minute and 5 minutes post-delivery.